Optimizing Injectable Poly-L-Lactic Acid Administration for Soft Tissue Augmentation: The Rationale for Three Treatment Sessions

Abstract

French

BACKGROUND

The availability and variety of different injectable modalities has led to a dramatic increase in soft tissue augmentation procedures in recent years. Injectable poly-L-lactic acid (PLLA) is a synthetic, biodegradable polymer device approved in the United States for use in immunocompetent patients as a single regimen of up to four treatment sessions for correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles. Injectable PLLA is also approved for restoration and/or correction of signs of facial fat loss (lipoatrophy) in individuals with HIV.

METHODS

The present article provides an overview of previous studies with injectable PLLA, and specifically focuses on the number of recommended treatment sessions and intervals between treatment sessions. The authors also provide two case studies to support their recommendations for an average of three treatment sessions.

RESULTS

Although the specific mechanisms remain hypothetical, injections of PLLA are believed to cause a cascade of cellular events that lead to collagen repair and subsequent restoration of facial volume. Because the development of a response to injectable PLLA is gradual and its duration of effect is long lasting, sufficient time between treatment sessions should be allocated to avoid overcorrection.

CONCLUSION

Studies of injectable PLLA support the hypothesized mode of operation, and the experience and clinical recommendations of the authors that suggest that three treatment sessions are an optimal regimen for use of injectable PLLA in the majority of patients.

Keywords

Collagen Cosmetic Dermal fillers Injectable devices Injectable PLLA

Get full access to this article

View all access options for this article.

References

American Society of Plastic Surgeons,. 2009 Report of the 2008 Statistics National Clearinghouse of Plastic Surgery Statistics. Arlington Heights: American Society of Plastic Surgeons, 2009.

Vleggaar

. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 2005; 31: 1511-7.

Donofrio

. Fat distribution: A morphologic study of the aging face. Dermatol Surg 2000; 26: 1107-12.

Garg

. Lipodystrophies. Am J Med 2000; 108: 143-52.

Ascher

, Coleman

, Alster

Full scope of effect of facial lipoatrophy: A framework of disease understanding.

Dermatol Surg 2006; 32: 1058-69.

Sterling

, Hanke

. Poly-L-lactic acid as a facial filler. Skin Ther Lett 2005; 10: 9-11.

Eppley

, Dadvand

. Injectable soft-tissue fillers: Clinical overview. Plast Reconstr Surg 2006; 118: 98e-106e.

Haneke

. Skin rejuvenation without a scalpel. I. Fillers. J Cosmet Dermatol 2006; 5: 157-67.

Juvéderm Ultra Plus. Santa Barbara: Allergan Inc, 2008.

10.

Lupo

, Smith

, Thomas

, Murphy

, Beddingfield

III . Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Reconstr Surg 2008; 121: 289-97.

11.

Narins

, Brandt

, Leyden

, Lorenc

, Rubin

, Smith

. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588-95.

12.

Carruthers

, Carey

, De Lorenzi

, Remington

, Schachter

, Sapra

. Randomized, double-blind comparison of the efficacy of two hyaluronic acid derivatives, Restylane Perlane and Hylaform, in the treatment of nasolabial folds. Dermatol Surg 2005; 31: 1591-8.

13.

Bosniak

, Cantisano-Zilkha

, Glavas

. Nonanimal stabilized hyaluronic acid for lip augmentation and facial rhytid ablation. Arch Facial Plast Surg 2004; 6: 379-83.

14.

Bauman

. CosmoDerm/CosmoPlast (human bioengineered collagen) for the aging face. Facial Plast Surg 2004; 20: 125-8.

15.

Baumann

, Kaufman

, Saghari

. Collagen fillers. Dermatol Ther 2006; 19: 134-40.

16.

Echavez

, Horstman

. Relationship between lipoatrophy and quality of life. AIDS Read 2005; 15: 369-75.

17.

Radiesse injectable implant. Franksville: BioForm Medical Inc, 2006.

18.

Sculptra Aesthetic,. Bridgewater: Dermik Laboratories, a business of sanofi-aventis U.S. LLC, 2009.

19.

Sculptra,. Bridgewater: Dermik Laboratories, a business of sanofi-aventis U.S. LLC, 2006.

20.

Valantin

M-A

, Aubron-Olivier

, Ghosn

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA.

AIDS 2003; 17: 2471-7.

21.

Moyle

, Lysakova

, Brown

A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.

HIV Med 2004; 5: 82-7.

22.

Moyle

, Brown

, Lysakova

, Barton

. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 2006; 7: 181-5.

23.

Bos

RRM

, Rozema

, Boering

Degradation of and tissue reaction to biodegradable poly(L-lactide) for use as internal fixation of fractures: A study in rats.

Biomaterials 1991; 12: 32-6.

24.

Gogolewski

, Jovanovic

, Perren

, Dillon

, Hughes

. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 1993; 27: 1135-48.

25.

Lemperle

, Morhenn

, Pestonjamasp

, Gallo

. Migration studies and histology of injectable microspheres of different sizes in mice. Plast Reconstr Surg 2004; 113: 1380-90.

26.

Böstman

, Viljanen

, Salminen

, Pihlajamäki

. Response of articular cartilage and subchondral bone to internal fixation devices made of poly-L-lactide: A histomorphometric and microradiographic study on rabbits. Biomaterials 2000; 21: 2553-60.

27.

Hasegawa

, Sakano

, Iwase

, Warashina

. The long-term behavior of poly-L-lactide screws in a minipig fracture model: Preliminary report. J Biomed Mater Res 2002; 63: 679-85.

28.

Pihlajamäki

, Böstman

, Tynninen

, Laitinen

. Long-term tissue response to bioabsorbable poly-L-lactide and metallic screws: An experimental study. Bone 2006; 39: 932-7.

29.

Rotunda

, Narins

. Poly-L-lactic acid: A new dimension in soft tissue augmentation. Dermatol Ther 2006; 19: 151-8.

30.

El-Beyrouty

, Huang

, Darnold

, Clay

. Poly-L-lactic acid for facial lipoatrophy in HIV. Ann Pharmacother 2006; 40: 1602-6.

31.

Keni

, Sidle

. Sculptra (injectable poly-L-lactic acid). Facial Plast Surg Clin North Am 2007; 15: 91-7, vii.

32.

Sherman

. Sculptra: The new three-dimensional filler. Clin Plast Surg 2006; 33: 539-50.

33.

Lowe

. Optimizing poly-L-lactic acid use. J Cosmet Laser Ther 2008; 10: 43-6.

34.

Beer

, Rendon

. Use of Sculptra in esthetic rejuvenation. Semin Cutan Med Surg 2006; 25: 127-31.

35.

Leonard

, Hanke

. A protocol for facial volume restoration with poly-L-lactic acid. J Drugs Dermatol 2006; 5: 872-7.

36.

Broder

, Cohen

. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 2006; 118: 7S-14S.

37.

Narins

, Bowman

. Injectable skin fillers. Clin Plast Surg 2005; 32: 151-62.

38.

Barton

, Engelhard

, Conant

. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: A review of the clinical studies. Int J STD AIDS 2006; 17: 429-35.

39.

Mest

, Humble

. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg 2006; 32: 1336-45.

40.

Narins

, Baumann

, Brandt

A randomized study of the efficacy and safety of injectable poly-L-lactic acid versus human-based collagen implant in the treatment of nasolabial fold wrinkles.

J Am Acad Dermatol 2010; 62: 448-62.

41.

American Society of Plastic Surgeons,. Perception of the Injection: American Women's Perception of Cosmetic Facial Injectables. a Harris Interactive Survey. <www.plasticsurgery.org/Documents/Media/Perception-of-the-Injection-American-Women-s-Perception-of-Cosmetic-Facial-Injectables.pdf> (Accessed on May 4, 2010).

42.

Narins

. Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg 2008; 34(Suppl 1):S100-S104.

43.

Lowe

, Maxwell

, Lowe

, Shah

, Patnaik

. Injectable poly-L-lactic acid: 3 years of aesthetic experience. Dermatol Surg 2009; 35(Suppl 1):344-9.

44.

Fitzgerald

, Vleggaar

, Burgess

. Facial dermal fillers. Aesthet Surg J 2008; 28: 699-701.

45.

Butterwick

, Lowe

. Injectable poly-L-lactic acid for cosmetic enhancement: Learning from the European experience. J Am Acad Dermatol 2009; 61: 281-93.

46.

Vleggaar

, Fitzgerald

. Dermatological implications of skeletal aging: A focus on supraperiosteal volumization for perioral rejuvenation. J Drugs Dermatol 2008; 7: 209-20.

47.

Day

, Littler

, Swift

, Gottlieb

. The Wrinkle Severity Rating Scale: A validation study. Am J Clin Dermatol 2004; 5: 49-52.

48.

Vander Straten

, Carrasco

, Paterson

, McCrary

, Meyer

, Tyring

. Tobacco use and skin disease. South Med J 2001; 94: 621-34.

49.

Freiman

, Bird

, Metelitsa

, Barankin

, Lauzon

. Cutaneous effects of smoking. J Cutan Med Surg 2004; 8: 415-23.

50.

Friedman

. Changes associated with the aging face. Facial Plast Surg Clin North Am 2005; 13: 371-80.

51.

Donath

, Glasgold

. Volume loss versus gravity: New concepts in facial aging. Curr Opin Otolaryngol Head Neck Surg 2007; 15: 238-43.

52.

Zins

, Moreira-Gonzalez

. Cosmetic procedures for the aging face. Clin Geriatr Med 2006; 22: 709-28.

53.

Lam

, Azizzadeh

, Graivier

. Injectable poly-L-lactic acid (Sculptra): Technical considerations in soft-tissue contouring. Plast Reconstr Surg 2006; 118: 55S-63S.

54.

Vleggaar

, Bauer

. Facial enhancement and the European experience with Sculptra (poly-L-lactic acid). J Drugs Dermatol 2004; 3: 542-7.

55.

Burgess

. Principles of soft tissue augmentation for the aging face. Clin Interv Aging 2006; 1: 349-55.

56.

Cohen

, Born

. Facial Rejuvenation with Fillers. In: Codner

, ed. London: Saunders Elsevier, 2009.